

## Regeneration therapy using autologous bone marrow derived M2 macrophage for severe heart failure


### Principal Investigator

The University of Osaka Hospital

**Assistant Professor Kizuku YAMASHITA**

### Project Outline

Excessive inflammation in heart failure causes adverse remodeling and accelerates the devastating situation. To date, various attempts of cell therapy have been done for this pathology. Of these, M2 macrophage is expected to be more effective as cell source.



However, the cell therapy with M2 macrophage has not been conducted so far. The aim of this study is to clarify its efficacy and safety in animal testing and try to move on clinical application in the future.

Following this experiment, we believe that many patients suffering from severe heart failure will be relieved by this less invasive cell therapy.

In order to apply basic patent, optimization of M2 macrophage cell therapy for severe heart failure is now in progress.

We are looking forward to seeing collaborators and companies aiming license out of our seeds.